08:03 AM EST, 11/11/2024 (MT Newswires) -- Arch Biopartners ( ACHFF ) says patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

The clinical team at the University of Calgary has dosed the first patient recruited for the study.

The University Health Network and Unity Health Toronto are also in the final stage of obtaining ethics and hospital approvals to start patient recruitment into the trial at Toronto General Hospital and St. Michael's Hospital, respectively, the company said in a statement.